Biosensors’ BioMatrix Flex DES Approved in Europe

January 22, 2010—Biosensors International Group, Ltd. (Singapore) announced that the company has received CE Mark approval for the BioMatrix Flex, a new version of its BioMatrix drug-eluting stent system, which was originally launched in Europe in April 2008. The BioMatrix Flex incorporates the company’s abluminal biodegradable polymer and Biolimus A9, which are features of the earlier device. The BioMatrix Flex stent will be commercially available in the coming months, the company stated.

Biosensors also announced that it has received approval for reimbursement in France for the BioMatrix. The device will be available to treat patients with coronary artery disease in France effective January 28. The device was launched in all other major European markets in April 2008 and is also available in other parts of the world including Asia and Latin America.